CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells

Human Pathology

Volumn 58, Issue , 2016, Pages 123-127

  Davidson, Ben ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

CD24; Diagnosis; Effusions; Mesothelioma; Ovarian carcinoma; Reactive mesothelial cells

Indexed keywords

CD24 ANTIGEN; CD24 PROTEIN, HUMAN; TUMOR MARKER;

ANATOMY; ARTICLE; BREAST CARCINOMA; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; EFFUSION; ENDOMETRIOID CARCINOMA; FEMALE; GENE EXPRESSION; HIGH GRADE SEROUS CARCINOMA; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MESOTHELIOMA; MESOTHELIUM CELL; OVARY CARCINOMA; TUMOR DIFFERENTIATION; BIOPSY; BREAST TUMOR; CANCER GRADING; CARCINOMA; COMPARATIVE STUDY; IMMUNOLOGY; LUNG TUMOR; NEOPLASM; OVARY TUMOR; PATHOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; VALIDATION STUDY;

ANTIGENS, CD24; BIOMARKERS, TUMOR; BIOPSY; BREAST NEOPLASMS; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MESOTHELIOMA; NEOPLASM GRADING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS;

EID: 84992145792     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2016.08.005     Document Type: Article

References (25)

1. [1] Davidson, B, Tropé, CG, Ovarian cancer - diagnostic, biological and prognostic aspects. Womens Health 10 (2014), 519–533.
2. [2] Davidson, B, Recently identified drug resistance biomarkers in ovarian cancer. Expert Rev Mol Diagn 16 (2016), 569–578.
3. [3] Jaggupilli, A, Elkord, E, Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity. Clin Dev Immunol, 2012, 2012, 708036.
4. [4] Burgos-Ojeda, D, Rueda, BR, Buckanovich, RJ, Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett 322 (2012), 1–7.
5. [5] Garson, K, Vanderhyden, BC, Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm. Reproduction 149 (2015), R59–R70.
6. [6] Davidson, B., Firat, P., Michael, C.W., (eds.) Serous effusions, 2011, Springer, London, UK.
7. [7] Davidson, B, Zhang, Z, Kleinberg, L, et al. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin Cancer Res 12 (2006), 5944–5950.
8. [8] Davidson, B, Holth, A, Hellesylt, E, et al. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage serous ovarian carcinoma effusions. HUM PATHOL 46 (2015), 1–8.
9. [9] Ordóñez, NG, Application of immunohistochemistry in the diagnosis of epithelioid mesothelioma: a review and update. HUM PATHOL 44 (2013), 1–19.
10. [10] Ordóñez, NG, Value of PAX8, PAX2, napsin a, carbonic anhydrase IX, and claudin-4 immunostaining in distinguishing pleural epithelioid mesothelioma from metastatic renal cell carcinoma. Mod Pathol 26 (2013), 1132–1143.
11. [11] Ordóñez, NG, Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas. Mod Pathol 26 (2013), 553–562.
12. [12] Laury, AR, Hornick, JL, Perets, R, et al. PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol 34 (2010), 627–635.
13. [13] Kawai, T, Tominaga, S, Hiroi, S, et al. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses. J Clin Pathol 69 (2016), 706–712.
14. [14] Gao, FF, Krasinskas, AM, Chivukula, M, Is PAX2 a reliable marker in differentiating diffuse malignant mesotheliomas of peritoneum from serous carcinomas of müllerian origin?. Appl Immunohistochem Mol Morphol 20 (2012), 272–276.
15. [15] Jo, VY, Cibas, ES, Pinkus, GS, Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology. Cancer Cytopathol 122 (2014), 299–306.
16. [16] Andrici, J, Jung, J, Sheen, A, et al. Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma. HUM PATHOL 51 (2016), 9–15.
17. [17] Kleinberg, L, Holth, A, Fridman, E, Schwartz, I, Shih, IM, Davidson, B, The diagnostic role of claudins in serous effusions. Am J Clin Pathol 127 (2007), 928–937.
18. [18] Davidson, B, Baekelandt, M, Shih, IM, MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagn Cytopathol 35 (2007), 756–760.
19. [19] Davidson, B, Stavnes, HT, Hellesylt, E, et al. MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions. HUM PATHOL 47 (2016), 104–108.
20. [20] Yuan, Y, Nymoen, DA, Tuft Stavnes, H, et al. Tenascin-X is a novel diagnostic marker of malignant mesothelioma. Am J Surg Pathol 33 (2009), 1673–1682.
21. [21] Zhu, J, Zhang, G, Lu, H, CD24, COX-2, and p 53 in epithelial ovarian cancer and its clinical significance. Front Biosci (Elite Ed) 4 (2012), 2745–2751.
22. [22] Kristiansen, G, Denkert, C, Schlüns, K, Dahl, E, Pilarsky, C, Hauptmann, S, CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 161 (2002), 1215–1221.
23. [23] Gao, MQ, Choi, YP, Kang, S, Youn, JH, Cho, NH, CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 29 (2010), 2672–2680.
24. [24] Meng, E, Long, B, Sullivan, P, et al. CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin Exp Metastasis 29 (2012), 939–948.
25. [25] Runz, S, Keller, S, Rupp, C, et al. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol 107 (2007), 563–571.